CA2273272C - Immediate release drug delivery forms - Google Patents

Immediate release drug delivery forms Download PDF

Info

Publication number
CA2273272C
CA2273272C CA002273272A CA2273272A CA2273272C CA 2273272 C CA2273272 C CA 2273272C CA 002273272 A CA002273272 A CA 002273272A CA 2273272 A CA2273272 A CA 2273272A CA 2273272 C CA2273272 C CA 2273272C
Authority
CA
Canada
Prior art keywords
microparticles
dosage unit
ibuprofen
poloxamer
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002273272A
Other languages
English (en)
French (fr)
Other versions
CA2273272A1 (en
Inventor
Steven E. Frisbee
Deirdre M. Barrow
Joseph Cascone
Barry D. Mccarthy
Bernard M. Kiernan
Hanan S. Anwar
Beuford A. Bogue
Claude Bayard
Abhijit Banerjee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valeant International Bermuda
Original Assignee
Fuisz Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/946,070 external-priority patent/US6013280A/en
Application filed by Fuisz Technologies Ltd filed Critical Fuisz Technologies Ltd
Publication of CA2273272A1 publication Critical patent/CA2273272A1/en
Application granted granted Critical
Publication of CA2273272C publication Critical patent/CA2273272C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002273272A 1997-10-07 1998-09-28 Immediate release drug delivery forms Expired - Fee Related CA2273272C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/946,070 US6013280A (en) 1997-10-07 1997-10-07 Immediate release dosage forms containing microspheres
US08/946,070 1997-10-07
US12916498A 1998-08-05 1998-08-05
US09/129,164 1998-08-05
PCT/US1998/020266 WO1999017744A1 (en) 1997-10-07 1998-09-28 Immediate release drug delivery forms

Publications (2)

Publication Number Publication Date
CA2273272A1 CA2273272A1 (en) 1999-04-15
CA2273272C true CA2273272C (en) 2004-09-21

Family

ID=26827301

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002273272A Expired - Fee Related CA2273272C (en) 1997-10-07 1998-09-28 Immediate release drug delivery forms

Country Status (7)

Country Link
EP (1) EP0966269A1 (de)
JP (1) JP2000507991A (de)
KR (1) KR20000069356A (de)
AU (1) AU9587198A (de)
BR (1) BR9806303A (de)
CA (1) CA2273272C (de)
WO (1) WO1999017744A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018106A1 (en) * 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Method of manufacturing solid dispersion
AU1323400A (en) * 1998-10-27 2000-05-15 Fuisz Technologies Ltd. Microparticles containing peg and/or peg glyceryl esters
IE981008A1 (en) * 1998-12-02 2000-06-14 Fuisz Internat Ltd Microparticles Containing Water Insoluble Active Agents
DZ3227A1 (fr) 1999-12-23 2001-07-05 Pfizer Prod Inc Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
US8980870B2 (en) * 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
US9149433B2 (en) * 2004-11-30 2015-10-06 Basf Corporation Method for formation of micro-prilled polymers
EP1897543A1 (de) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine-Waffel zur Substitutionstherapie
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1388786A (en) * 1972-04-03 1975-03-26 Scherer Corp R P Integral solid gel-lattice dosage form of high-moisture content
DE3927113C2 (de) * 1989-08-17 1993-11-25 Dolorgiet Gmbh & Co Kg Mittel zur Behandlung von schweren Schmerzzuständen und Verfahren zu ihrer Herstellung
CA2095776C (en) * 1992-05-12 2007-07-10 Richard C. Fuisz Rapidly dispersable compositions containing polydextrose
CA2118517C (en) * 1992-06-10 2003-10-14 Gary G. Liversidge Surface modified nsaid nanoparticles
US5683720A (en) * 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
JPH11514979A (ja) * 1995-09-07 1999-12-21 フイズ テクノロジーズ リミテッド 実質的に非溶解性の生体作用薬剤をバイオ・アベイラブルにするシステム

Also Published As

Publication number Publication date
EP0966269A1 (de) 1999-12-29
JP2000507991A (ja) 2000-06-27
KR20000069356A (ko) 2000-11-25
WO1999017744A1 (en) 1999-04-15
BR9806303A (pt) 2000-03-14
CA2273272A1 (en) 1999-04-15
AU9587198A (en) 1999-04-27

Similar Documents

Publication Publication Date Title
CA2821046C (en) An hiv protease inhibitor solid dosage formulation for the treatment of hiv/aids
EP0636370B1 (de) Morphinenthaltende Arzneizusammensetzungen mit verzögerter Wirkstoffabgabe
KR100554816B1 (ko) 비결정질 넬피나비르 메실레이트의 약학 제형
EP0531611B1 (de) Verzögerte Freigabe-Matrix für Arzneimittel
CN100379407C (zh) 生产咀嚼分散片的方法
US5879705A (en) Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
JP6666490B2 (ja) Ｃｇｒｐ活性化合物の錠剤製剤
MXPA01012889A (es) Composiciones farmaceuticas orales de liberacion controlada y sabor disfrazado.
JP2010509289A (ja) チロシンキナーゼ阻害剤の経口投与用薬学的剤形
US5851555A (en) Controlled release dosage forms containing water soluble drugs
KR20070119700A (ko) 페노피브레이트 및 계면 활성제 혼합물을 함유하는 제제
CA2273272C (en) Immediate release drug delivery forms
TW201609195A (zh) 固體抗病毒劑型
US5879714A (en) Controlled-release pharmaceutical compositions
NZ260883A (en) Oral sustained-release medicaments containing morphine
JP2002528042A (ja) 改善された放出特性を有する投与形態
IE981008A1 (en) Microparticles Containing Water Insoluble Active Agents
AU2002319154B2 (en) Pharmaceutical dosage form of amorphous nelfinavir mesylate
AU2002319154A1 (en) Pharmaceutical dosage form of amorphous nelfinavir mesylate

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed